First reported by ft.com
AstraZeneca shares slide 9% after heart treatment disappoints in trial
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
From the article
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
Continue reading on STATYou might also wanna read
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
thehindubusinessline.com·7h ago
AstraZeneca loses £20bn in value after major heart drug trial setback
Londonlovesbusiness·3h ago
Major drugmaker loses $27 billion in market value after failed trial
MarketWatch·5h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The Independent·4h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
ireland-live.ie·4h ago
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta
finans.dk·6h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.